Log in to your Inderes Free account to see all free content on this page.
Modus Therapeutics Holding
1.3
SEK
MODTX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
0%
-13.91%
-27.98%
+3.59%
-15.58%
-28.77%
-56.67%
-
-75.24%
Modus Therapeutics operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company's focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered. The activities with associated research are conducted in Sweden.
Read moreMarket cap
46.72M SEK
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
14.5.
2025
Interim report Q1'25
20.5.
2025
General meeting '25
27.8.
2025
Interim report Q2'25
ShowingAll content types
Modus Therapeutics to Present LPS Study Data at Pharmacology 2024
Modus Therapeutics Initiates Phase II Study with Sevuparin for the Treatment of Chronic Kidney Disease with Anemia
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio